On #rarediseaseday and every day we are proud of the work we are doing to support patients suffering from #Kennedysdisease (SBMA) - a rare neuromuscular disorder. We look forward to a day when a treatment will be available for SBMA patients and for all patients suffering from rare diseases.
关于我们
Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease. Additional pipeline programs center around a novel target with the potential to address multiple disease mechanisms and that has broad clinical application across neurodegenerative and peripheral inflammatory diseases. We are creating a sustainable pipeline for the company by utilizing a functional genomics discovery platform based on human cell lines to identify novel targets. Through our approach we seek to transform patient lives in meaningful ways. www.nidobio.com.
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
- 创立
- 2018
Nido Biosciences员工
动态
-
Our CEO?Jeremy P Springhorn, PhD was featured alongside other industry leaders in the latest installment of “Scrip Asks What Does 2025 Hold for Biopharma?” Check it out to learn why Jeremy predicts #raredisease drug development is on the rise in 2025:?https://bit.ly/3XhP1p3
-
-
We are excited to announce a new publication in?Neurology?, the medical journal of the American Academy of Neurology.?This collaborative research reveals clinically meaningful endpoints for Spinal and Bulbar Muscular Atrophy. Led by our team, researchers from institutions around the world contributed their individual natural history studies that were integrated to generate the?largest global SBMA dataset known to date. Through robust analyses of this dataset, highly sensitive functional endpoints were identified that will inform future interventional clinical trials in SBMA. Research that drives a better understanding of disease evolution metrics, like this publication, allows us to design more efficient clinical studies to assess the impact of therapies for people suffering from this debilitating disease. See the full publication here: https://bit.ly/41hvlEw
-
Nido Bio's CEO, Jeremy P Springhorn, PhD and CMO, Vissia Viglietta, are here at Kennedy's Disease Association’s Annual Conference in Orlando, Florida. We’re continually inspired by this community that works together to advance research and build the foundation for new therapeutic options for SBMA patients.
-
-
We’re attending Kennedy's Disease Association’s Annual Conference in Orlando, Florida from November 2-4. We’re honored to partner with KDA and participate in this important event each year.?Nido Bio will share updates on our fully enrolled NIDO-361 Phase 2 study. ? Learn more about KDA here: bit.ly/4e7bdI7
-
There’s a lot going on at Nido Bio! ? We are so pleased to share that the European Medicines Agency has granted Orphan Drug Designation to our lead clinical candidate NIDO-361. The EMA’s designation illustrates the lack of satisfactory treatment options for patients with SBMA, also known as Kennedy’s Disease, and enables us to seek scientific advice, amongst other benefits, as we continue the?development of the program.? ? This comes at a critical time?as?we’ve fully enrolled our Phase 2?global?trial of NIDO-361.?The rapid enrollment of this trial is a testament to our dedication to patients suffering from this rare and debilitating disease.? ? Want to learn more about what this designation and full enrollment means for SBMA patients? Read the release here: https://bit.ly/4heBozg
-
Not just science, we’re also passionate about food! We gathered to celebrate summer and enjoy paella, prepared by our CEO, Jeremy P Springhorn, PhD, for an al fresco #team dinner.? ? Learn more about the #people who power Nido Bio at?https://nidobio.com/
-
-
A publication highlighting Nido's research, resulting in a robust and novel set of fluid protein biomarkers in spinal and bulbar muscular atrophy (#SBMA), was published today in The Journal of Clinical Investigation Insight. In the published study, researchers identified 40 highly reproducible SBMA-associated proteins,?associated with the underlying metabolic, neuronal and muscle biology of the disease across multiple independent data sets. With a limited number of sensitive biomarkers that support clinical research for #SBMA,?also known as #KennedysDisease, these discoveries could substantially support the growth of research toward finding an effective therapeutic for patients who can’t wait any longer. We'd like to thank our collaborators at UCL,?The National Institutes of Health and?University of Oxford for their support in identifying these biomarkers. See the publication here:?bit.ly/4cx3lQ2
-
Congratulations to Marc Swikalus, CPA, MBA, Nido Bio’s new Vice President of Finance. ? Marc joined Nido Bio in 2021. He has 25 years of experience working in the biopharmaceutical development, software and public accounting industries.? ? We are grateful for Marc’s years of dedication to helping find a therapeutic option for patients suffering from #SBMA and we welcome him to the company’s #leadership team.
-
-
Congratulations to Dan Jacobs on making it as a finalist on Bravo TV’s #TopChef Season 21. Living with #SBMA, also known as #KennedysDisease, Dan faced physical disadvantages against already strong competition. People like Dan inspire us to push the boundaries of neuroscience toward a therapeutic option for this devastating disease.? ?